| Perrin E Romine, MD | |
|
21632 Highway 99, Edmonds, WA 98026-8032 | |
| (425) 673-8300 | |
| (425) 673-8301 |
| Full Name | Perrin E Romine |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine - Medical Oncology |
| Location | 21632 Highway 99, Edmonds, Washington |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1174984074 | NPI | - | NPPES |
| 2060351 | Medicaid | WA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RX0202X | Internal Medicine - Medical Oncology | MD60866550 (Washington) | Primary |
| Entity Name | Swedish Health Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689612954 PECOS PAC ID: 0244138196 Enrollment ID: O20031230000187 |
News Archive
Among elderly Americans, women and those with diabetes and dementia are most likely to find themselves in the Medicare Part D drug plan 'doughnut hole,' the coverage gap that occurs after a beneficiary has reached the annual coverage limit but hasn't spent enough on drugs to qualify for catastrophic coverage.
A new analysis of data on more than 900 Baltimore adults by Johns Hopkins Medicine researchers has linked stressful life experiences among middle-aged women - but not men - to greater memory decline in later life.
Aerocrine AB announces that a nine-member council representing both prestigious asthma societies, the American Academy and the American College of Allergy, Asthma and Immunology (ACAAI and AAAAI), have published a position statement in support of the clinical practice guideline on Aerocrine's FeNO test as published by the ATS.
A new study supports the use of a DNA-based "biomarker" blood test as a complement to the prostate-specific antigen (PSA) test currently offered to screen men for prostate cancer. University of Cincinnati (UC) researchers report their findings online ahead of print in the British Journal of Cancer.
Cell Therapeutics, Inc. announced today that CTI received a statement on March 1, 2010 from the Gynecologic Oncology Group (GOG) leadership that the phase III GOG-212 clinical trial of CTI's OPAXIO™ used as maintenance therapy for ovarian cancer remains a high priority and enrollment will continue. The GOG made the statement to clarify that the recent results of the GOG-218 clinical trial bevacizumab in maintenance therapy for ovarian cancer has not influenced the importance of completing the GOG-212 clinical trial.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Perrin E Romine, MD Po Box 25608, Salt Lake City, UT 84125-0608 Ph: (206) 320-4476 | Perrin E Romine, MD 21632 Highway 99, Edmonds, WA 98026-8032 Ph: (425) 673-8300 |
News Archive
Among elderly Americans, women and those with diabetes and dementia are most likely to find themselves in the Medicare Part D drug plan 'doughnut hole,' the coverage gap that occurs after a beneficiary has reached the annual coverage limit but hasn't spent enough on drugs to qualify for catastrophic coverage.
A new analysis of data on more than 900 Baltimore adults by Johns Hopkins Medicine researchers has linked stressful life experiences among middle-aged women - but not men - to greater memory decline in later life.
Aerocrine AB announces that a nine-member council representing both prestigious asthma societies, the American Academy and the American College of Allergy, Asthma and Immunology (ACAAI and AAAAI), have published a position statement in support of the clinical practice guideline on Aerocrine's FeNO test as published by the ATS.
A new study supports the use of a DNA-based "biomarker" blood test as a complement to the prostate-specific antigen (PSA) test currently offered to screen men for prostate cancer. University of Cincinnati (UC) researchers report their findings online ahead of print in the British Journal of Cancer.
Cell Therapeutics, Inc. announced today that CTI received a statement on March 1, 2010 from the Gynecologic Oncology Group (GOG) leadership that the phase III GOG-212 clinical trial of CTI's OPAXIO™ used as maintenance therapy for ovarian cancer remains a high priority and enrollment will continue. The GOG made the statement to clarify that the recent results of the GOG-218 clinical trial bevacizumab in maintenance therapy for ovarian cancer has not influenced the importance of completing the GOG-212 clinical trial.
› Verified 5 days ago
Alexander C Chung, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 21601 76th Ave W, Edmonds, WA 98026 Phone: 425-640-4000 Fax: 425-640-4010 | |
Shen-li Tan, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 7320 216th St Sw, Ste 210, Edmonds, WA 98026 Phone: 425-744-1777 Fax: 425-744-1790 | |
Anita Chopra, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 7320 216th St Sw Ste 200, Edmonds, WA 98026 Phone: 425-640-4900 Fax: 425-640-4919 | |
Drake William Cramer, DO Internal Medicine Medicare: Medicare Enrolled Practice Location: 7320 216th St Sw Ste 200, Edmonds, WA 98026 Phone: 425-640-4900 Fax: 425-640-4919 | |
Douglas D Mcmillen, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 23320 Hwy 99, Edmonds, WA 98026 Phone: 425-640-5500 Fax: 425-640-5520 | |
Dr. Elaine Yilin Shao, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 21600 Highway 99 Ste 230, Edmonds, WA 98026 Phone: 206-215-4250 Fax: 206-215-4252 | |
Andrew Knubel Perry, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 21710 76th Ave W, Suite 300, Edmonds, WA 98026 Phone: 425-640-5500 Fax: 425-640-5520 |